-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ATyr Pharma, Inc. (NASDAQ:LIFE) Short Interest Up 5.4% in August
ATyr Pharma, Inc. (NASDAQ:LIFE) Short Interest Up 5.4% in August
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 341,600 shares, a growth of 5.4% from the August 15th total of 324,000 shares. Based on an average trading volume of 131,700 shares, the days-to-cover ratio is presently 2.6 days.
aTyr Pharma Stock Down 3.9 %
LIFE stock opened at $2.93 on Wednesday. The firm's fifty day moving average is $3.49 and its 200 day moving average is $3.76. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10.
Get aTyr Pharma alerts:aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). During the same quarter in the previous year, the company earned ($0.64) earnings per share. On average, research analysts forecast that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. StockNews.com downgraded shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Wednesday, September 14th. HC Wainwright raised their price target on aTyr Pharma from $11.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, July 21st. Finally, Piper Sandler increased their price objective on aTyr Pharma from $11.00 to $14.00 and gave the company an "overweight" rating in a research report on Monday, August 15th.Insider Activity
In other news, CEO Sanjay Shukla bought 15,000 shares of the firm's stock in a transaction that occurred on Friday, July 1st. The shares were acquired at an average price of $2.88 per share, with a total value of $43,200.00. Following the acquisition, the chief executive officer now owns 40,798 shares of the company's stock, valued at approximately $117,498.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.36% of the stock is owned by company insiders.
Hedge Funds Weigh In On aTyr Pharma
Large investors have recently bought and sold shares of the stock. Raymond James & Associates bought a new position in shares of aTyr Pharma in the fourth quarter worth approximately $184,000. Dimensional Fund Advisors LP raised its stake in shares of aTyr Pharma by 1.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 226,712 shares of the biotechnology company's stock valued at $1,694,000 after acquiring an additional 2,433 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma during the fourth quarter worth about $87,000. Tikvah Management LLC bought a new stake in shares of aTyr Pharma in the fourth quarter worth about $9,157,000. Finally, GSA Capital Partners LLP purchased a new stake in aTyr Pharma in the 4th quarter worth approximately $439,000. 65.58% of the stock is owned by hedge funds and other institutional investors.
aTyr Pharma Company Profile
(Get Rating)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Recommended Stories
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 341,600 shares, a growth of 5.4% from the August 15th total of 324,000 shares. Based on an average trading volume of 131,700 shares, the days-to-cover ratio is presently 2.6 days.
ATyr医药公司(纳斯达克:LIFE-GET评级)看到空头股数在8月份有显著增长。截至8月31日,空头股数共有34.16万股,较8月15日的32.4万股增长5.4%。基于131,700股的平均成交量,目前的天数与回补比率为2.6天。
aTyr Pharma Stock Down 3.9 %
ATyr Pharma股价下跌3.9%
LIFE stock opened at $2.93 on Wednesday. The firm's fifty day moving average is $3.49 and its 200 day moving average is $3.76. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10.
人寿股票周三开盘报2.93美元。该公司的50日移动均线切入位为3.49美元,200日移动均线切入位为3.76美元。ATyr Pharma的52周低点为2.60美元,52周高点为13.10美元。
aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). During the same quarter in the previous year, the company earned ($0.64) earnings per share. On average, research analysts forecast that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.
ATyr医药(纳斯达克:LIFE-GET评级)最近一次公布季度收益数据是在8月15日(星期一)。这家生物技术公司公布的季度每股收益(EPS)为0.44美元,低于分析师普遍预期的0.43美元和0.01美元。去年同期,该公司每股收益为0.64美元。研究分析师平均预测,aTyr Pharma本财年每股收益将达到1.81美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Insider Activity
内幕活动
In other news, CEO Sanjay Shukla bought 15,000 shares of the firm's stock in a transaction that occurred on Friday, July 1st. The shares were acquired at an average price of $2.88 per share, with a total value of $43,200.00. Following the acquisition, the chief executive officer now owns 40,798 shares of the company's stock, valued at approximately $117,498.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.36% of the stock is owned by company insiders.
在其他新闻方面,首席执行官桑贾伊·舒克拉在7月1日星期五的一笔交易中购买了15,000股该公司的股票。这些股票是以每股2.88美元的平均价格收购的,总价值为43,200.00美元。收购完成后,这位首席执行官现在拥有40,798股公司股票,价值约117,498.24美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在此超链接。4.36%的股份由公司内部人士持有。
Hedge Funds Weigh In On aTyr Pharma
对冲基金参与aTyr Pharma
Large investors have recently bought and sold shares of the stock. Raymond James & Associates bought a new position in shares of aTyr Pharma in the fourth quarter worth approximately $184,000. Dimensional Fund Advisors LP raised its stake in shares of aTyr Pharma by 1.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 226,712 shares of the biotechnology company's stock valued at $1,694,000 after acquiring an additional 2,433 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma during the fourth quarter worth about $87,000. Tikvah Management LLC bought a new stake in shares of aTyr Pharma in the fourth quarter worth about $9,157,000. Finally, GSA Capital Partners LLP purchased a new stake in aTyr Pharma in the 4th quarter worth approximately $439,000. 65.58% of the stock is owned by hedge funds and other institutional investors.
大型投资者最近买卖了该股的股票。Raymond James&Associates在第四季度购买了价值约18.4万美元的aTyr Pharma股票的新头寸。Dimension Fund Advisors LP在第四季度将其在aTyr Pharma的股份增加了1.1%。Dimension Fund Advisors LP现在拥有226,712股这家生物技术公司的股票,价值1,694,000美元,此前在上个季度又购买了2,433股。Qube Research&Technologies Ltd在第四季度购买了aTyr Pharma价值约8.7万美元的新股。Tikvah Management LLC在第四季度购买了aTyr Pharma价值约9,157,000美元的新股。最后,GSA Capital Partners LLP在第四季度购买了aTyr Pharma的新股份,价值约43.9万美元。65.58%的股票由对冲基金和其他机构投资者持有。
aTyr Pharma Company Profile
ATyr制药公司简介
(Get Rating)
(获取评级)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
ATyr Pharma,Inc.是一家生物疗法公司,在美国从事基于新免疫途径的药物的发现和开发。该公司的主要候选药物是efzofitimod,这是一种NRP2的选择性调节剂,正在进行肺结节病的第二阶段临床试验;以及1b/2a阶段的临床试验,用于治疗其他间质性肺部疾病,如慢性过敏性肺炎和与ILD相关的结缔组织疾病。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- 免费获取StockNews.com关于aTyr Pharma(LIFE)的研究报告
- 连续60年提高股息的3只防御性股票
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但并未出局
- 如果你渴望价值,那就尝尝露丝的好客之道吧
- 福特在第三季度发出警告后是否正在反弹
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受aTyr Pharma Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对aTyr Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧